首页 > 最新文献
paperpass

Nature Reviews Neurology最新文献

英文 中文
Translating Parkinson disease genetics into clinical benefit. 将帕金森病遗传学转化为临床益处。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-11-09 DOI: 10.1038/s41582-026-01283-y
Micol Avenali, Alberto Imarisio, Enza Maria Valente

Parkinson disease (PD) is a heterogeneous neurodegenerative disorder characterized by variable progression and treatment response. Over the past three decades, genetic discoveries have reshaped our understanding of PD biology, identifying rare monogenic forms, strong genetic risk variants and a large set of common and rare genetic variants variably contributing to PD heritability. These findings led to the identification of key pathways implicated in the neurodegenerative process, including protein misprocessing, lysosomal and mitochondrial impairment, and altered immune response. In this Review, we describe the evolution of PD genetics and discuss its current clinical impact and future role in shaping precision medicine, from diagnosis and prognosis to the development of disease-modifying therapies. Genetic information is increasingly used to support clinical decision-making, improve patient counselling and identify biologically distinct forms of PD. Importantly, genetic insights are driving therapeutic innovation, enabling targeted strategies and genetically stratified clinical trials. Despite ongoing challenges such as incomplete penetrance, variable expression of disease and missing heritability across multiple ancestries, integrating genetic knowledge into research and clinical practice is accelerating the transition towards precision medicine in PD, providing a framework for more personalized care and improved patient outcomes.

帕金森病(PD)是一种异质性神经退行性疾病,其特点是不同的进展和治疗反应。在过去的三十年里,遗传学的发现重塑了我们对帕金森病生物学的理解,发现了罕见的单基因形式、强遗传风险变异和大量常见和罕见的遗传变异,这些变异在一定程度上影响了帕金森病的遗传性。这些发现导致识别神经退行性过程中涉及的关键途径,包括蛋白质错误加工,溶酶体和线粒体损伤以及免疫反应改变。在这篇综述中,我们描述了PD遗传学的发展,并讨论了其目前的临床影响和未来在塑造精准医学中的作用,从诊断和预后到疾病改善疗法的发展。遗传信息越来越多地用于支持临床决策,改善患者咨询和识别生物学上不同形式的PD。重要的是,基因的见解正在推动治疗创新,使有针对性的策略和基因分层的临床试验成为可能。尽管存在不完全外显率、疾病的可变表达和多祖先遗传缺失等挑战,但将遗传知识整合到PD的研究和临床实践中,正在加速PD向精准医学的过渡,为更个性化的护理和改善患者的治疗效果提供了一个框架。
{"title":"Translating Parkinson disease genetics into clinical benefit.","authors":"Micol Avenali, Alberto Imarisio, Enza Maria Valente","doi":"10.1038/s41582-026-01283-y","DOIUrl":"https://doi.org/10.1038/s41582-026-01283-y","url":null,"abstract":"<p><p>Parkinson disease (PD) is a heterogeneous neurodegenerative disorder characterized by variable progression and treatment response. Over the past three decades, genetic discoveries have reshaped our understanding of PD biology, identifying rare monogenic forms, strong genetic risk variants and a large set of common and rare genetic variants variably contributing to PD heritability. These findings led to the identification of key pathways implicated in the neurodegenerative process, including protein misprocessing, lysosomal and mitochondrial impairment, and altered immune response. In this Review, we describe the evolution of PD genetics and discuss its current clinical impact and future role in shaping precision medicine, from diagnosis and prognosis to the development of disease-modifying therapies. Genetic information is increasingly used to support clinical decision-making, improve patient counselling and identify biologically distinct forms of PD. Importantly, genetic insights are driving therapeutic innovation, enabling targeted strategies and genetically stratified clinical trials. Despite ongoing challenges such as incomplete penetrance, variable expression of disease and missing heritability across multiple ancestries, integrating genetic knowledge into research and clinical practice is accelerating the transition towards precision medicine in PD, providing a framework for more personalized care and improved patient outcomes.</p>","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":" ","pages":""},"PeriodicalIF":31.2,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting cranial bone marrow-derived inflammation in chronic TBI. 针对慢性创伤性脑损伤的颅骨髓源性炎症。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-11-09 DOI: 10.1038/s41582-026-01290-z
Lisa Kiani
{"title":"Targeting cranial bone marrow-derived inflammation in chronic TBI.","authors":"Lisa Kiani","doi":"10.1038/s41582-026-01290-z","DOIUrl":"https://doi.org/10.1038/s41582-026-01290-z","url":null,"abstract":"","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":" ","pages":""},"PeriodicalIF":31.2,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel BTK inhibitor reduces multiple sclerosis relapses. 新型BTK抑制剂减少多发性硬化症复发。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-11-09 DOI: 10.1038/s41582-026-01291-y
Heather Wood
{"title":"Novel BTK inhibitor reduces multiple sclerosis relapses.","authors":"Heather Wood","doi":"10.1038/s41582-026-01291-y","DOIUrl":"https://doi.org/10.1038/s41582-026-01291-y","url":null,"abstract":"","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":" ","pages":""},"PeriodicalIF":31.2,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hormonal changes must be part of the conversation in neurological care. 激素的变化必须是神经系统护理的一部分。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-11-09 DOI: 10.1038/s41582-026-01289-6
Maria Bonaria Uccheddu
{"title":"Hormonal changes must be part of the conversation in neurological care.","authors":"Maria Bonaria Uccheddu","doi":"10.1038/s41582-026-01289-6","DOIUrl":"https://doi.org/10.1038/s41582-026-01289-6","url":null,"abstract":"","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":" ","pages":""},"PeriodicalIF":31.2,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CAR T cells show early promise in progressive multiple sclerosis. CAR - T细胞在进展性多发性硬化症中显示出早期的希望。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-11-06 DOI: 10.1038/s41582-026-01292-x
Heather Wood
{"title":"CAR T cells show early promise in progressive multiple sclerosis.","authors":"Heather Wood","doi":"10.1038/s41582-026-01292-x","DOIUrl":"https://doi.org/10.1038/s41582-026-01292-x","url":null,"abstract":"","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":" ","pages":""},"PeriodicalIF":31.2,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149371304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dementia risk reduction can start in the doctor's office. 降低痴呆症风险可以从医生的办公室开始。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-11-05 DOI: 10.1038/s41582-026-01284-x
Miia Kivipelto, Francesca Mangialasche
{"title":"Dementia risk reduction can start in the doctor's office.","authors":"Miia Kivipelto, Francesca Mangialasche","doi":"10.1038/s41582-026-01284-x","DOIUrl":"https://doi.org/10.1038/s41582-026-01284-x","url":null,"abstract":"","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":" ","pages":""},"PeriodicalIF":31.2,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149343046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of animal models to understand CNS neuroimmunology - guidance from the International Society for Neuroimmunology White Paper Task Force. 使用动物模型来理解中枢神经系统神经免疫学——来自国际神经免疫学学会白皮书工作组的指导。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-10-26 DOI: 10.1038/s41582-026-01272-1
Jennifer L Gommerman, Katerina Akassoglou, Sergio E Baranzini, Burkhard Becher, Fabienne Brilot, Gonçalo Castelo-Branco, Shannon E Dunn, Maryam Faiz, Alexander Flügel, Nader Ghasemlou, Erin M Gibson, Judith M Greer, Denis Gris, Cole A Harrington, Steffen Jung, Lorraine V Kalia, Thomas Korn, Gurumoorthy Krishnamoorthy, Roland S Liblau, Francesca Odoardi, Laura Piccio, Anne-Katrin Pröbstel, Francisco J Quintana, Valeria Ramaglia, Manu Rangachari, Olga L Rojas, Marc J Ruitenberg, Scott Russo, Dorothy P Schafer, Benjamin M Segal, Jana Vukovic, Chao Wang, Michael A Wheeler, Heinz Wiendl, V Wee Yong, Frauke Zipp, Veronique E Miron

Neuroimmunology is a rapidly expanding field in which many breakthroughs have been fuelled by studies in animal models that capture aspects of human neurological disease. However, the variety of animal models available, with their relative merits and drawbacks, is not well documented in the literature, posing a hurdle for scientists who are venturing into the world of neuroimmunology. Moreover, nuances between animal models, their utility for studying neuroimmunological processes and the variables that affect their associated clinical and pathological outcomes can affect the reproducibility and clinical relevance of findings at the preclinical stage. In this Review, the International Society of Neuroimmunology White Paper Task Force describes animal models that can be used to study neuroimmunological aspects of neurological disease and the intrinsic and extrinsic factors that affect readouts from these models. We provide guidance on how to manipulate these factors to gain insight into neuroimmunology and to control them for improved reproducibility. We also consider the advantages and limitations of available tools, including robust genetic systems, neuroimmunological imaging, functional readouts and omics-based cell profiling. Finally, we discuss how animal models have advanced drug development to treat neuroimmunological diseases and how the same principles can provide insight into a variety of neurological disorders. We aim to provide guidance on how to optimize the use of animal models to gain insight into neuroimmunological mechanisms and support the preclinical drug discovery pipeline.

神经免疫学是一个迅速发展的领域,许多突破都是由动物模型研究推动的,这些研究捕捉了人类神经系统疾病的各个方面。然而,各种可用的动物模型,以及它们的相对优点和缺点,并没有在文献中得到很好的记录,这给那些冒险进入神经免疫学世界的科学家们带来了障碍。此外,动物模型之间的细微差别,它们在研究神经免疫学过程中的效用,以及影响其相关临床和病理结果的变量,可能会影响临床前阶段研究结果的可重复性和临床相关性。在这篇综述中,国际神经免疫学学会白皮书工作组描述了可用于研究神经系统疾病的神经免疫学方面的动物模型以及影响这些模型读数的内在和外在因素。我们提供指导,如何操纵这些因素,以获得洞察神经免疫学和控制他们,以提高再现性。我们还考虑了现有工具的优点和局限性,包括强大的遗传系统,神经免疫成像,功能读数和基于组学的细胞谱。最后,我们讨论了动物模型如何促进药物开发来治疗神经免疫疾病,以及相同的原理如何为各种神经系统疾病提供见解。我们的目标是为如何优化动物模型的使用提供指导,以深入了解神经免疫学机制,并支持临床前药物发现管道。
{"title":"Use of animal models to understand CNS neuroimmunology - guidance from the International Society for Neuroimmunology White Paper Task Force.","authors":"Jennifer L Gommerman, Katerina Akassoglou, Sergio E Baranzini, Burkhard Becher, Fabienne Brilot, Gonçalo Castelo-Branco, Shannon E Dunn, Maryam Faiz, Alexander Flügel, Nader Ghasemlou, Erin M Gibson, Judith M Greer, Denis Gris, Cole A Harrington, Steffen Jung, Lorraine V Kalia, Thomas Korn, Gurumoorthy Krishnamoorthy, Roland S Liblau, Francesca Odoardi, Laura Piccio, Anne-Katrin Pröbstel, Francisco J Quintana, Valeria Ramaglia, Manu Rangachari, Olga L Rojas, Marc J Ruitenberg, Scott Russo, Dorothy P Schafer, Benjamin M Segal, Jana Vukovic, Chao Wang, Michael A Wheeler, Heinz Wiendl, V Wee Yong, Frauke Zipp, Veronique E Miron","doi":"10.1038/s41582-026-01272-1","DOIUrl":"10.1038/s41582-026-01272-1","url":null,"abstract":"<p><p>Neuroimmunology is a rapidly expanding field in which many breakthroughs have been fuelled by studies in animal models that capture aspects of human neurological disease. However, the variety of animal models available, with their relative merits and drawbacks, is not well documented in the literature, posing a hurdle for scientists who are venturing into the world of neuroimmunology. Moreover, nuances between animal models, their utility for studying neuroimmunological processes and the variables that affect their associated clinical and pathological outcomes can affect the reproducibility and clinical relevance of findings at the preclinical stage. In this Review, the International Society of Neuroimmunology White Paper Task Force describes animal models that can be used to study neuroimmunological aspects of neurological disease and the intrinsic and extrinsic factors that affect readouts from these models. We provide guidance on how to manipulate these factors to gain insight into neuroimmunology and to control them for improved reproducibility. We also consider the advantages and limitations of available tools, including robust genetic systems, neuroimmunological imaging, functional readouts and omics-based cell profiling. Finally, we discuss how animal models have advanced drug development to treat neuroimmunological diseases and how the same principles can provide insight into a variety of neurological disorders. We aim to provide guidance on how to optimize the use of animal models to gain insight into neuroimmunological mechanisms and support the preclinical drug discovery pipeline.</p>","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":" ","pages":""},"PeriodicalIF":31.2,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149271285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitochondrial dysfunction in neurology: biomarkers and clinical implications. 神经病学中的线粒体功能障碍:生物标志物和临床意义。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-10-23 DOI: 10.1038/s41582-026-01274-z
Elena Rossini, Matteo Garibaldi, Michael G Hanna, Robert D S Pitceathly, Chiara Pizzamiglio

Mitochondrial dysfunction is increasingly recognized as a shared downstream pathogenic mechanism across a wide spectrum of neurological disorders, ranging from primary mitochondrial diseases to conditions including amyotrophic lateral sclerosis, Alzheimer disease, Parkinson disease, multiple sclerosis, hereditary ataxias and idiopathic inflammatory myopathies. This Review examines the role of mitochondrial biomarkers in improving diagnostic accuracy, patient stratification and monitoring of disease progression and therapeutic response. Primary mitochondrial diseases are presented as proof-of-concept models of impaired oxidative phosphorylation, providing a framework for biomarker identification and validation with translational relevance to other neurological diseases. Mitochondrial biomarkers can be broadly categorized into four domains: fluid biomarkers, reflecting metabolic alterations and stress signalling; genetic biomarkers, capturing mitochondrial DNA integrity and dynamics; multi-omics approaches, integrating transcriptomic, proteomic and metabolomic signatures; and imaging biomarkers, enabling in vivo assessment of structural and functional consequences of mitochondrial dysfunction. Across disorders, these biomarkers reveal shared disturbances in bioenergetics, redox homeostasis, mitochondrial genome maintenance and inflammatory signalling. However, clinical implementation remains limited by methodological heterogeneity, biological variability and reduced disease specificity. Integrated, multimodal biomarker strategies, combined with longitudinal validation, will be essential for supporting precision medicine and guiding the development of therapies to target mitochondrial pathways in neurology.

线粒体功能障碍越来越被认为是广泛的神经系统疾病的共同下游致病机制,从原发性线粒体疾病到肌萎缩性侧索硬化症、阿尔茨海默病、帕金森病、多发性硬化症、遗传性共济失调和特发性炎性肌病。这篇综述探讨了线粒体生物标志物在提高诊断准确性、患者分层和监测疾病进展和治疗反应方面的作用。原发性线粒体疾病作为氧化磷酸化受损的概念验证模型,为生物标志物鉴定和验证提供了一个框架,并与其他神经系统疾病的翻译相关。线粒体生物标志物大致可分为四个领域:流体生物标志物,反映代谢变化和应激信号;遗传生物标志物,捕捉线粒体DNA的完整性和动态;多组学方法,整合转录组学、蛋白质组学和代谢组学特征;成像生物标志物,能够在体内评估线粒体功能障碍的结构和功能后果。在各种疾病中,这些生物标志物揭示了生物能量学、氧化还原稳态、线粒体基因组维持和炎症信号的共同干扰。然而,临床应用仍然受到方法学异质性、生物学变异性和疾病特异性降低的限制。综合的、多模式的生物标志物策略,结合纵向验证,对于支持精准医学和指导神经病学中针对线粒体途径的治疗发展至关重要。
{"title":"Mitochondrial dysfunction in neurology: biomarkers and clinical implications.","authors":"Elena Rossini, Matteo Garibaldi, Michael G Hanna, Robert D S Pitceathly, Chiara Pizzamiglio","doi":"10.1038/s41582-026-01274-z","DOIUrl":"https://doi.org/10.1038/s41582-026-01274-z","url":null,"abstract":"<p><p>Mitochondrial dysfunction is increasingly recognized as a shared downstream pathogenic mechanism across a wide spectrum of neurological disorders, ranging from primary mitochondrial diseases to conditions including amyotrophic lateral sclerosis, Alzheimer disease, Parkinson disease, multiple sclerosis, hereditary ataxias and idiopathic inflammatory myopathies. This Review examines the role of mitochondrial biomarkers in improving diagnostic accuracy, patient stratification and monitoring of disease progression and therapeutic response. Primary mitochondrial diseases are presented as proof-of-concept models of impaired oxidative phosphorylation, providing a framework for biomarker identification and validation with translational relevance to other neurological diseases. Mitochondrial biomarkers can be broadly categorized into four domains: fluid biomarkers, reflecting metabolic alterations and stress signalling; genetic biomarkers, capturing mitochondrial DNA integrity and dynamics; multi-omics approaches, integrating transcriptomic, proteomic and metabolomic signatures; and imaging biomarkers, enabling in vivo assessment of structural and functional consequences of mitochondrial dysfunction. Across disorders, these biomarkers reveal shared disturbances in bioenergetics, redox homeostasis, mitochondrial genome maintenance and inflammatory signalling. However, clinical implementation remains limited by methodological heterogeneity, biological variability and reduced disease specificity. Integrated, multimodal biomarker strategies, combined with longitudinal validation, will be essential for supporting precision medicine and guiding the development of therapies to target mitochondrial pathways in neurology.</p>","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":" ","pages":""},"PeriodicalIF":31.2,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149245702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multi-organ imaging genetics: towards an integrated view of brain, body and brain diseases. 多器官成像遗传学:迈向脑、身体和脑疾病的综合观点。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-10-19 DOI: 10.1038/s41582-026-01276-x
Zirui Fan, Bingxin Zhao

Population-based cohorts that combine genetic data with whole-body multimodal imaging are transforming how we map the genetic architecture of the brain in its broader bodily context. Historically, imaging genetics has focused largely on single organs, especially the brain, with separate efforts targeting the heart, skeleton and other organs for systemic diseases, and limited integration across organ systems. Yet, strong brain-body interactions and the high multimorbidity of brain and systemic diseases highlight the need for a brain-centred multi-organ perspective. Here we introduce the emerging field of brain-focused multi-organ imaging genetics, outlining key data resources and interdisciplinary analytical frameworks for large-scale multi-organ genetic discovery and reviewing the genetic associations between brain diseases and imaging phenotypes across organ systems. We discuss how these advances support a whole-body integrated view of brain health and disease and how they are beginning to reshape clinical translation for neurological conditions. We outline a roadmap for agentic artificial intelligence co-scientists that work alongside human researchers throughout the scientific discovery process, arguing that such systems will be essential for achieving an integrated understanding of brain health and disease, both as tools for individual researchers and as a collaborative infrastructure for the whole field.

将遗传数据与全身多模态成像相结合的基于人群的队列正在改变我们在更广泛的身体背景下绘制大脑遗传结构的方式。从历史上看,成像遗传学主要关注单个器官,特别是大脑,而针对心脏、骨骼和其他器官的系统性疾病的单独努力,以及跨器官系统的有限整合。然而,强烈的脑-体相互作用以及脑和全身性疾病的高发病率突出了以脑为中心的多器官视角的必要性。在这里,我们介绍了以脑为中心的多器官成像遗传学的新兴领域,概述了大规模多器官遗传发现的关键数据资源和跨学科分析框架,并回顾了脑疾病与跨器官系统成像表型之间的遗传关联。我们讨论了这些进展如何支持大脑健康和疾病的全身综合观点,以及它们如何开始重塑神经系统疾病的临床翻译。我们为在整个科学发现过程中与人类研究人员一起工作的人工智能合作科学家概述了路线图,认为这样的系统对于实现对大脑健康和疾病的综合理解至关重要,既可以作为个人研究人员的工具,也可以作为整个领域的协作基础设施。
{"title":"Multi-organ imaging genetics: towards an integrated view of brain, body and brain diseases.","authors":"Zirui Fan, Bingxin Zhao","doi":"10.1038/s41582-026-01276-x","DOIUrl":"https://doi.org/10.1038/s41582-026-01276-x","url":null,"abstract":"<p><p>Population-based cohorts that combine genetic data with whole-body multimodal imaging are transforming how we map the genetic architecture of the brain in its broader bodily context. Historically, imaging genetics has focused largely on single organs, especially the brain, with separate efforts targeting the heart, skeleton and other organs for systemic diseases, and limited integration across organ systems. Yet, strong brain-body interactions and the high multimorbidity of brain and systemic diseases highlight the need for a brain-centred multi-organ perspective. Here we introduce the emerging field of brain-focused multi-organ imaging genetics, outlining key data resources and interdisciplinary analytical frameworks for large-scale multi-organ genetic discovery and reviewing the genetic associations between brain diseases and imaging phenotypes across organ systems. We discuss how these advances support a whole-body integrated view of brain health and disease and how they are beginning to reshape clinical translation for neurological conditions. We outline a roadmap for agentic artificial intelligence co-scientists that work alongside human researchers throughout the scientific discovery process, arguing that such systems will be essential for achieving an integrated understanding of brain health and disease, both as tools for individual researchers and as a collaborative infrastructure for the whole field.</p>","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":" ","pages":""},"PeriodicalIF":31.2,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Menopause-associated proteomic changes link to brain ageing and dementia risk 与更年期相关的蛋白质组变化与大脑老化和痴呆风险有关。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-10-09 DOI: 10.1038/s41582-026-01278-9
Lisa Kiani
Proteomic changes associated with menopause track with cognitive ageing and dementia risk, according to new research.
根据一项新的研究,与更年期相关的蛋白质组学变化与认知衰老和痴呆风险有关。
{"title":"Menopause-associated proteomic changes link to brain ageing and dementia risk","authors":"Lisa Kiani","doi":"10.1038/s41582-026-01278-9","DOIUrl":"10.1038/s41582-026-01278-9","url":null,"abstract":"Proteomic changes associated with menopause track with cognitive ageing and dementia risk, according to new research.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 11","pages":"664-664"},"PeriodicalIF":31.2,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Nature Reviews Neurology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
mjeditor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1